Form 4: CalciMedica's Chief Medical Officer, Sudarshan Hebbar, Reports Stock Option Grant

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, reports the acquisition of stock options.

Summary

• Sudarshan Hebbar, Chief Medical Officer of CalciMedica, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on March 28, 2024, where Hebbar acquired 82,500 employee stock options with an exercise price of $4.16.
• These options vest in equal monthly installments over four years, starting from the grant date.
• Following the reported transaction, Hebbar directly owns 82,500 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The document is a routine SEC filing regarding stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning management with shareholder interests, but it's a standard practice.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 1/48th per month over four years is a typical vesting arrangement.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its competitiveness.

Stakeholder Impact

• The stock option grant could incentivize the Chief Medical Officer to improve company performance, benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates